UK-based pharmaceutical firm Indivior has stated that it is taking organisational and cost actions to adjust its abilities and resources to meet its strategic priorities.
Indivior has suffered a critical defeat in the US courts for opioid addiction product Suboxone Film, opening the door to generic competition and sparking a run on its shares.